Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-beta-D-glucopyranosylacetamide is a synthetic small molecule belonging to the class of hexoses (six-carbon monosaccharides). It is structurally related to glucose derivatives and acts as an experimental inhibitor of glycogen phosphorylase, specifically the muscle form. By inhibiting this enzyme, it can potentially modulate glycogen metabolism. The compound has been studied primarily in biochemical and structural contexts as a tool compound for understanding enzyme inhibition but has not advanced into clinical development or therapeutic use[2][5]. Its main research interest lies in its potential as a lead structure for designing antihyperglycemic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-beta-D-glucopyranosylacetamide.